HALO Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own HALO shares is 669, representing 101.56% of the company's common stock.

2XIDEAS AG, in the last quarter, reduced its stake in HALO by -5.27% restricting it's holding to 515.46 thousand shares of worth nearly $20.97M. KENNEDY CAPITAL MANAGEMENT LLC also lessened -22.59% of the HALO shares from its portfolio, reducing its holding to 513.1 thousand shares of worth $20.87M. PRICE T ROWE ASSOCIATES INC /MD/ also shunned HALO shares holding by -6.55% last quarter which brought its holding to 1.3 million shares worth $52.84M.

As per its latest 13F filing, MAN GROUP PLC increased its stake in HALO by 15.03% in the last quarter. The institutional holder raised its holding to 400.07 thousand shares having worth more than $16.27M. CERITY PARTNERS LLC also added 9.66% more shares of HALO to its portfolio, raising its holding to 295.54 thousand shares of worth $12.02M. FISHER ASSET MANAGEMENT, LLC also increased its HALO shares holding by 0.06% which brought its holding to 277.07 thousand shares worth $11.27M.

The insider with the most stakes in HALO is Torley Helen , PRESIDENT AND CEO at the company. Additionally, HALO stock is highly held by director MATSUI CONNIE and director Kelley Kenneth J among others.

Company executives, directors, and other insiders own 1.06% percent of Halozyme Therapeutics, Inc.'s stock. Within the last six months, there have been 22 transaction(s) in which HALO insiders have sold stock, totaling 159.5K shares. Insiders that have sold shares include HENDERSON JEFFREY WILLIAM, LABARRE MICHAEL J., and TORLEY HELEN.

There have been 0 transaction(s) during the past 6-months in which Halozyme Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 8.8M Halozyme Therapeutics, Inc. shares are held by insiders, which represents about 1.06% of HALO stock.

HALO PRESIDENT AND CEO, Torley Helen holds the largest portfolio of the company's shares. HALO shares owned by Torley total nearly 676.74 thousand.

MAN GROUP PLC is the largest institutional owner in HALO which holds 400.07 thousand shares worth $16.27M or 0.32% of the total HALO shares outstanding followed by CERITY PARTNERS LLC with ownership of 295.54 thousand shares representing 0.23% of the HALO ownership. FISHER ASSET MANAGEMENT, LLC is the third largest stakeholder with 277.07 thousand shares or 0.21% of the ownership worth more than $11.27M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the HALO is concerned, it is a stock which is optionable.

Number of HALO shares short is 9.50M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 127.23M shares of HALO are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, HALO has 125.89M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for HALO is 7.28.